Indeed, blocking IL-1 signaling with monoclonal antibodies targeting the interleukin 1 receptor accessory protein (IL1RAP and IL1R3) has been shown to have an antileukemic effect on CML and AML cells in vivo [27,28]. This evidence concerns the gene IL1B and acute myeloid leukemia.